Indication

Treatment of patients aged 1 year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.

Medicine details

Medicine name:
teduglutide (Revestive)
SMC ID:
SMC2225
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Gastro-intestinal system
Submission type
Resubmission
Status
Publication due date:
Q1 2020
SMC meeting date:
Q1 2020
Patient group submission deadline:
04 November 2019